Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing-Reference-Cited by-同舟云学术

Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing

Published:2022-10-14 Issue:11 Volume:12 Page:2517-2529
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Giuliano Claudio^ORCID,Frizzarin Stefano^ORCID,Alonzi Alessandro^ORCID,Stimamiglio Virginia^ORCID,Ortiz-Romero Pablo L.^ORCID

Funder

Helsinn

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00813-y.pdf

Reference41 articles.

1. Denis D, Beneton N, Laribi K, et al. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res. 2019;11:2241–51.

2. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14.

3. Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-an update 2021. Hematol Oncol. 2021;39(Suppl 1):46–51.

4. Scarisbrick J. Staging of mycosis fungoides and Sézary syndrome: time for an update? EMJ Hematology. 2018;6(1):92–100.

5. National Comprehensive Cancer Network. Primary cutaneous lymphomas (version 2.2022). 2022. https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. Accessed 27 July 2022.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chlormethine gel in combination with other therapies for treatment of mycosis fungoides: a review with patient cases;Frontiers in Medicine;2024-01-11

2. Mechanism of action of chlormethine gel in mycosis fungoides;Journal of the European Academy of Dermatology and Venereology;2023-07

3. MFM-300(Sc): a chemically stable Sc(iii)-based MOF material for multiple applications;Chemical Communications;2023

4. An Overview of the EORTC-CLTG 2022 Congress;EMJ Oncology;2022-11-14